[ad_1]
AstraZeneca Inc.’s COVID-19 vaccine sales more than tripled in the second quarter to $ 894 million from the first quarter, but the drugmaker again delayed its US application for approval on Thursday while it collects more data to submit the request.
The AstraZeneca vaccine is a key weapon in the fight against the Corona pandemic because it is cheaper and easier to use than some competing vaccines.
AstraZeneca and its manufacturing partner in India claim to have sold 1 billion doses in 170 countries so far.
The company started work on the vaccine last year in cooperation with the University of Oxford. Today, he said he expects to receive US approval for the vaccine in the second half of this year.
Shares of the company fell 1.4% early in the session, but made up for losses and rose during the session.
Total revenue of $ 8.22 billion for the three months to June exceeded analysts’ expectations of $ 7.58 billion, but basic earnings of 90 cents per share were lower than estimates by 92 cents.
Source link
